IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS

被引：0
|
作者：
Pierola, A. Alfonso [1 ]
Montalban-Bravo, G. [1 ]
Takahashi, K. [1 ]
Jabbour, E. J. [1 ]
Kadia, T. [1 ]
Ravandi, F. [1 ]
Cortes, J. [1 ]
DiNardo, C. [1 ]
Daver, N. [1 ]
Borthakur, G. [1 ]
Pemmaraju, N. [1 ]
Konopleva, M. [1 ]
Bueso-Ramos, C. [2 ]
Pierce, S. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Hematopathol, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P665
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [21] A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients
    Zhang, Ludan
    Ge, Rui
    Pan, Deng
    Yue, Pengjie
    Zhang, Jingwen
    Bian, Renjie
    Yan, Xiaojing
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Topotecan A topoisomerase 1 inhibitor induces complete remissions in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).
    Beran, M
    OBrien, S
    Estey, E
    Keating, M
    Kantarjian, H
    BLOOD, 1996, 88 (10) : 2308 - 2308
  • [23] Monocyte Subset Analysis Accurately Distinguishes Chronic Myelomonocytic Leukemia (CMML) from Myelodysplastic Syndromes (MDS) and Is Associated with a Favorable MDS Prognosis
    Talati, Chetasi
    Zhang, Ling
    Shaheen, Ghada
    Kuykendall, Andrew
    Ball, Markus
    Zhang, Qing
    Lancet, Jeffrey E.
    Zuckerman, Kenneth S.
    List, Alan F.
    Komrokji, Rami S.
    Moscinski, Lynn C.
    Padron, Eric
    BLOOD, 2016, 128 (22)
  • [24] Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
    Duchmann, M.
    Braun, T.
    Micol, J-B
    Platzbecker, U.
    Park, S.
    Pilorge, S.
    Beyne-Rauzy, O.
    Vey, N.
    Sebert, M.
    Gruson, B.
    Dumas, P-Y
    Guieze, R.
    Chretien, M-L
    Laribi, K.
    Chait, Y.
    Legros, L.
    Sahnes, L.
    Hirsch, P.
    Salanoubat, C.
    Solary, E.
    Fenaux, P.
    Itzykson, R.
    BLOOD CANCER JOURNAL, 2017, 7 : e562 - e562
  • [25] SYSTEMATIC REVIEW OF THERAPY USED IN HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Bell, J.
    Galaznik, A.
    Huelin, R.
    Stokes, M.
    Seal, B.
    Fram, R.
    Faller, D. V.
    LEUKEMIA RESEARCH, 2017, 55 : S80 - S81
  • [26] Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Fraison, Jean-Baptiste
    Mekinian, Arsene
    Grignano, Eric
    Kahn, Jean-Emmanuel
    Arlet, Jean-Benoit
    Decaux, Olivier
    Guillaume, Denis
    Buchdahl, Anne-Laure
    Omouri, Mohamed
    Maigne, Gwenola
    Aouba, Achille
    Leon, Nathalie
    Berthier, Sabine
    Liozon, Eric
    Park, Sophie
    Gardin, Claude
    Lortholary, Olivier
    Rossignol, Julien
    Fenaux, Pierre
    Fain, Olivier
    Braun, Thorsten
    BLOOD, 2015, 126 (23)
  • [27] Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
    M Duchmann
    T Braun
    J-B Micol
    U Platzbecker
    S Park
    S Pilorge
    O Beyne-Rauzy
    N Vey
    M Sébert
    B Gruson
    P-Y Dumas
    R Guieze
    M-L Chretien
    K Laribi
    Y Chait
    L Legros
    L Sahnes
    P Hirsch
    C Salanoubat
    E Solary
    P Fenaux
    R Itzykson
    Blood Cancer Journal, 2017, 7 : e562 - e562
  • [28] Epigenetic Mechanisms Underlying the Pathogenesis of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Cheng, J. X.
    Anastasi, J.
    Shen, J. Q.
    Watanabe, K.
    Grimley, E.
    Kleinbrink, E.
    Knibbs, R.
    Roulston, D.
    Vardiman, J. W.
    MODERN PATHOLOGY, 2012, 25 : 329A - 330A
  • [29] Epigenetic Mechanisms Underlying the Pathogenesis of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Cheng, J. X.
    Anastasi, J.
    Shen, J. Q.
    Watanabe, K.
    Grimley, E.
    Kleinbrink, E.
    Knibbs, R.
    Roulston, D.
    Vardiman, J. W.
    LABORATORY INVESTIGATION, 2012, 92 : 329A - 330A
  • [30] Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
    Darbaniyan, Faezeh
    Zheng, Hong
    Kanagal-Shamanna, Rashmi
    Lockyer, Pamela
    Montalban-Bravo, Guillermo
    Estecio, Marcos
    Lu, Yue
    Soltysiak, Kelly A.
    Chien, Kelly S.
    Yang, Hui
    Sasaki, Koji
    Class, Caleb
    Ganan-Gomez, Irene
    Do, Kim-Anh
    Garcia-Manero, Guillermo
    Wei, Yue
    EXPERIMENTAL HEMATOLOGY, 2022, 115 : 44 - 53
12345